Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry

被引:2
|
作者
Politei, J. M. [1 ]
Cabrera, G. [2 ]
Amartino, H. [3 ]
Valdez, R. [4 ]
Masllorens, F. [5 ]
Ripeau, D. [6 ]
Antongiovanni, N. [7 ]
Soliani, A. [8 ]
Luna, P. [9 ]
Cedrolla, M. [10 ]
Fernandez, S. [11 ]
Fainboim, A. [12 ]
机构
[1] Juan Fernandez Hosp, Neurol Serv, RA-1878 Buenos Aires, DF, Argentina
[2] Del Viso Med Ctr, Serv Cardiol, Buenos Aires, DF, Argentina
[3] Austral Hosp, Neuropediatr Serv, Buenos Aires, DF, Argentina
[4] Cent Mil Hosp, Genet Serv, Buenos Aires, DF, Argentina
[5] Posadas Hosp, Genet Serv, Buenos Aires, DF, Argentina
[6] Posadas Hosp, Serv Nephrol, Buenos Aires, DF, Argentina
[7] Pergamino Clin, Serv Nephrol, Buenos Aires, DF, Argentina
[8] Cosme Argerich Hosp, Dermatol Serv, Buenos Aires, DF, Argentina
[9] German Hosp, Dermatol Serv, Buenos Aires, DF, Argentina
[10] High Complex Hosp, Neurol Serv, Formosa, Argentina
[11] Ciperca Srl, Serv Nephrol, Catamarca, Argentina
[12] Ricardo Gutierrez Hosp, Serv Pediat, Buenos Aires, DF, Argentina
关键词
NATURAL-HISTORY DATA; AGALSIDASE BETA TREATMENT; ALPHA-GALACTOSIDASE; RENAL-DISEASE; REPLACEMENT THERAPY; DIALYSIS; FEMALES; LIFE;
D O I
10.1111/ijcp.12081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Fabry disease (FD) is an X-linked inborn error of metabolism caused by alpha-galactosidase A deficiency. The Fabry Registry is an ongoing, global observational database that compiles clinical data from patients with FD. Methods: Demographic and baseline clinical characteristics of Fabry Registry patients enrolled in Argentina were analysed and compared with patients enrolled in the rest of the world (ROW). Baseline clinical parameters included chronic kidney disease (CKD) stage, urine protein-to-creatinine ratio and left ventricular posterior wall thickness. Only data from untreated patients were included. Results: As of 1 October 2010, 3752 patients were enrolled in the Registry, 70 patients from Argentina and 3682 from the ROW. Argentinean male subjects were younger than Fabry Registry male subjects enrolled in ROW: mean current age 32.5 years vs. 39.0 years for men (p = 0.0257 by t-test). The current age (mean +/- standard deviation) of female subjects enrolled in Argentina was not significantly different from that of female subjects enrolled in the ROW: 40.1 +/- 17.28 vs. 43.2 +/- 17.95 years respectively (p = 0.2967). Overall, a smaller percentage of patients from Argentina received ERT compared with patients in the ROW (54% vs. 58% respectively). When evaluated by gender, more men and fewer women in Argentina received ERT compared with ROW (85% vs. 79% for men and 27% vs. 38% for women). A larger proportion of patients in ROW had severe CKD (stage 4 or 5) compared with Argentina (9.8% vs. 0%), most likely because of the older age of the ROW population. Conclusions: The enrolment of Argentinean patients into the Fabry Registry has steadily increased, as has the inclusion of female and paediatric patients with FD. The medical community in Argentina should be aware of FD in these populations, as awareness will facilitate prompt diagnosis and initiation of treatment, thus leading to improved outcomes.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [41] Fabry disease: experience of screening dialysis patients for Fabry disease
    Eiji Kusano
    Osamu Saito
    Tetsu Akimoto
    Yasushi Asano
    Clinical and Experimental Nephrology, 2014, 18 : 269 - 273
  • [42] Prevalence of Lymphedema in Anderson-Fabry Disease a Report From the Fabry Registry
    Jefferies, John L.
    Hopkin, Robert
    CIRCULATION, 2018, 138
  • [43] Fabry disease: experience of screening dialysis patients for Fabry disease
    Kusano, Eiji
    Saito, Osamu
    Akimoto, Tetsu
    Asano, Yasushi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (02) : 269 - 273
  • [44] Fabry disease: Delineating the natural history of the disorder through the Fabry Registry.
    Eng, CM
    Banikazemi, M
    Barranger, J
    Charrow, J
    Clark, L
    Bushinsky, D
    Hopkin, R
    Pastores, G
    Scott, CR
    Sims, K
    Wilcox, W
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 453 - 453
  • [45] Life expectancy and cause of death in Fabry disease: Findings from the Fabry Registry
    Banikazemi, Maryam
    Patel, Manesh
    Lemay, Roberta
    Waldek, Stephen
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (02) : S10 - S10
  • [46] Fabry cardiomyopathy in Finland: A Fabry registry study
    Effati, Paivi Pietila
    Valtola, Kati
    Walls, Susanne
    Kantola, Ilkka
    Kuusisto, Johanna
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S97 - S98
  • [47] Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry
    West, Michael L.
    Bichet, Daniel G.
    Iwanochko, Mark
    Khan, Aneal
    Sirrs, Sandra
    LeMoine, Kaye M.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 135 - 135
  • [48] Reduced incidence of stroke in patients with Fabry disease treated with agalsidase beta: A matched analysis from the Fabry Registry
    Burlina, Alessandro
    Al-Shaar, Laila
    Germain, Dominique P.
    Banikazemi, Maryam
    Ponceb, Elvira
    Crespo, Ana
    Lawson, Victoria
    Politei, Juan
    MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02) : 16 - 16
  • [49] Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
    Watt, Torquil
    Burlina, Alessandro P.
    Cazzorla, Chiara
    Schoenfeld, Dorothee
    Banikazemi, Maryam
    Hopkin, Robert J.
    Martins, Ana Maria
    Sims, Katherine
    Beitner-Johnson, Dana
    O'Brien, Fanny
    Feldt-Rasmussen, Ulla
    GENETICS IN MEDICINE, 2010, 12 (11) : 703 - 712
  • [50] Natural history data from 182 female patients with Fabry disease in Latin America: A Fabry Registry analysis of disease burden
    Martins, Ana Maria
    Varas, Carmen
    Molt, Fernando
    Lemay, Roberta
    Politei, Juan M.
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S91 - S92